Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative ECF chemotherapy for operable locally advanced gastric cancer
ACTRN12605000701628Phase 2Completed
- Sponsor
- AGITG sponsored trial conducted through NHMRC CTC
- Start
- Dec 1996
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of epirubicin, fluorouracil and cisplatin in gastric cancer (GC), sponsored by AGITG sponsored trial conducted through NHMRC CTC. Primary endpoints: chemotherapy morbidity, chemotherapy mortality and 3 more. Started Dec 1996; status: completed.
02
Drugs
epirubicinfluorouracilcisplatin
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on ACTRN12605000701628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12605000701628.